The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -0.25 (-1.20%)
Spread: 1.00 (5.00%)
Open: 20.75
High: 20.75
Low: 20.50
Prev. Close: 20.75
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate & Trading Update

14 Jul 2015 07:00

RNS Number : 9305S
Iofina PLC
14 July 2015
 

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

CORPORATE & TRADING UPDATE

 

EBITDA Positive in H1 2015

Record Iodine Production in H1 2015 - an Increase of 110% year on year

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to update the market today on a strong performance in the first half of the financial year ("H1 2015"), and a record quarter for crystalline iodine production in the second quarter of 2015 ("Q2 2015").

The Company produced a quarterly record of 166.2 metric tons (MT) of crystalline iodine in Q2 2015 (Q2 2014: 92.9MT) and a record of 294.1MT in H1 2015 (H1 2014: 139.9MT) which is an increase of 110 per cent, exceeding Company expectations. During the period, the Company shut IO#1 and focused its iodine production operations in the Company's core area. This operational focus has resulted in increased production at all of the Company's five operating IOsorb® iodine plants, compared with previous periods. The Board is delighted to report that the Company was EBITDA positive in H1 2015.

 

Iofina expects to produce between 260-300MT of crystalline iodine in H2 2015 from its five operating IOsorb® plants. The Company is anticipating scheduled preventative maintenance during H2 and lower seasonal production in Q4 due to weather, which is reflected in the provided guidance. Iodine pricing continues to remain below historical trends and the Company expects this trend to continue throughout 2015.

 

On 2 July 2015, the Company filed in the state of Montana First District Court a Petition for Judicial Review of the Final Order of the Respondent Montana Department of Natural Resources and Conservation ("DNRC") in the Matter of the Application for Beneficial Water Use Permit No. 40S 30066181. The estimated timetable for this review is expected to be in the order of six to nine months for this non-core water depot project.

Commenting on today's news, President and CEO Dr. Tom Becker, stated: "The Company has focused on operational excellence and, as a result, has produced record levels of crystalline iodine for the first half of the year at each of its five operating IOsorb® plants." 

 

"Against the backdrop of a challenging iodine market, where prices are below historical trends, the Company is committed to operating in the most efficient manner possible, and reducing its production costs. As a result of these measures and our record production performance, the Company has been EBITDA positive for the first half of 2015. Iofina Chemical has continued to perform well in a competitive market. We are committed to focusing on the Company's core areas of iodine and specialty halogen derivative production. To this end, the Company continues to explore, with its partners, plans for additional future lower cost iodine production."

 

 

 

 

For further information, please contact:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Joanna Weaving

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Rob Collins/Emily Morris

GMP Securities

Tel: +44(0)20 7647 2800

 

Dominic Barretto

Yellow Jersey PR Limited

Tel: +44 (0)7768 537 739

About Iofina:

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDBGDRLSBBGUX
Date   Source Headline
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.